Catalent Pharma Solutions, Inc. - FORM 10-K - EX-12.1 - STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES - September 16, 2011

Attached files

file filename
10-K - FORM 10-K - Catalent Pharma Solutions, Inc.d232612d10k.htm
EX-2.5 - STOCK PURCHASE AGREEMENT - Catalent Pharma Solutions, Inc.d232612dex25.htm
EX-21.1 - LIST OF SUBSIDIARIES - Catalent Pharma Solutions, Inc.d232612dex211.htm
EX-31.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) - Catalent Pharma Solutions, Inc.d232612dex312.htm
EX-10.6 - LETTER AGREEMENT - Catalent Pharma Solutions, Inc.d232612dex106.htm
EX-32.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 - Catalent Pharma Solutions, Inc.d232612dex321.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A) - Catalent Pharma Solutions, Inc.d232612dex311.htm
EX-32.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 - Catalent Pharma Solutions, Inc.d232612dex322.htm
EX-10.36 - FORM OF NONQUALIFIED STOCK OPTION AGREEMENT (DAVID HEYENS) - Catalent Pharma Solutions, Inc.d232612dex1036.htm

Exhibit 12.1

Statement Regarding Computation of Ratio of Earnings to Fixed Charges

 

      Successor           Predecessor  

(in millions, except for ratios)

    For the
Fiscal
Year
Ended
June 30,
2011		     For the
Fiscal
Year
Ended
June 30,
2010		     For the
Fiscal
Year
Ended
June 30,
2009		     For the
Fiscal
Year
Ended
June 30,
2008		     For the
Fiscal
Year
Ended
June 30,
2007		     For the
Period
April 10,
2007 to
June 30,
2007		           For the
Period
July 1,
2006 to
April 9,
2007		  

Earnings/(loss) from continuing operations before income taxes and noncontrolling interest

    $ (15.4 )    $ (246.1 )    $ (234.3 )    $ (542.7 )    $ (134.9 )    $ (168.0 )         $ 33.1   

Plus Fixed Charges:

                    

Interest expense

      166.0        161.6        183.2        204.3        58.1        45.6             12.5   

Capital interest

      0.1        1.4        —          —          —          —               —     

Estimated interest within rental expense

      6.0        6.7        6.6        4.6        0.9        0.9             3.6   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

         

 

 

  

Total Fixed Charges

      172.1        169.7        189.8        208.9        59.0        46.5             16.1   

Plus: amortization of capitalized interest

      1.5        2.5        2.5        2.5        0.3        0.3             0.5   

Less: Interest expense capitalized

      0.1        1.4        —          —          —          —               —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

         

 

 

  

Earnings

      158.1        (75.3 )      (42.0 )      (331.3 )      (75.6 )      (121.2 )           49.7   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

         

 

 

  

Ratio of earnings to fixed charges

                       3.1   

Shortfall

      (14.0 )      (245.0 )      (231.8 )      (540.2 )      (134.6 )      (167.7 )        

Catalent Pharma Solutions, Inc. Reports

Also read